胃肠道肿瘤手术同期腹壁疝补片修补的术后结局
基于ACS NSQIP数据库2016—2022年数据,3449例胃肠道恶性肿瘤切除同期行开放腹壁疝修补的患者中仅6.5%使用补片。倾向性评分匹配后,补片修补未增加30天手术部位软组织感染率,但手术时间、住院时间及再入院、输血、再手术等并发症更高。
要点
- 胃肠道肿瘤切除同期补片疝修补仅占6.5%,需严格选择患者。
- 补片修补未增加30天手术部位软组织感染(7.5% vs 5.6%,p=0.410)。
- 补片修补与更长手术时间、住院时间及更高再入院、输血、再手术相关。
核心结论
- 胃肠道肿瘤切除同期补片腹壁疝修补未增加30天手术部位软组织感染,但围术期并发症和再入院等风险更高。
研究设计与样本
- 回顾性队列研究,查询ACS NSQIP数据库2016—2022年胃肠道恶性肿瘤切除同期开放腹壁疝修补患者,共3449例,其中224例(6.5%)使用补片。
- 采用1:2倾向性评分匹配,匹配后补片组174例、原发性修补组305例,比较围术期结局。
主要发现
- 匹配后补片组手术时间更长(242.5 vs 170分钟,p<0.001),住院时间更长(7 vs 5天,p=0.002)。
- 补片组总体并发症率更高(43.1% vs 28.2%,p=0.001),但手术部位软组织感染率无显著差异(7.5% vs 5.6%,p=0.410)。
- 补片组再入院率(20.7% vs 11.5%,p=0.006)、输血率(20.7% vs 10.5%,p=0.006)和再手术率(8.6% vs 3.6%,p=0.020)均更高。
临床怎么用
- 胃肠道肿瘤切除同期补片疝修补需权衡补片修补的耐久性与增加的围术期并发症风险,严格选择患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent ventral hernia repair with mesh (mVHR) at the time of gastrointestinal (GI) cancer resection remains controversial due to concerns of increased skin and soft tissue infections (SSTIs) and mesh-related complications, which may delay receipt of systemic cancer therapies and affect both surgical and oncologic outcomes. Given the health and quality-of-life burden imposed by hernias, we sought to analyze the safety of concurrent mVHR and GI cancer resection. STUDY DESIGN: The American College of Surgeons NSQIP database was queried for patients who underwent resection of GI malignancy and concurrent open VHR (with and without mesh) from 2016 to 2022. Perioperative outcomes of mVHR vs primary VHR (pVHR) were assessed before and after 1:2 propensity score matching. The primary outcome was 30-day postoperative SSTI rate. RESULTS: Of 3,449 patients undergoing concurrent VHR with GI cancer resection, 224 (6.5%) underwent mVHR. After matching (n = 174 mVHR; n = 305 pVHR), mVHR was found to be associated with longer operative time (242.5 vs 170 minutes, p < 0.001) and length of stay (7 vs 5 days, p = 0.002). The overall complication rate was higher in the mVHR cohort (43.1% vs 28.2%, p = 0.001), but there was no significant difference in SSTI rate (7.5% vs 5.6%, p = 0.410). mVHR was associated with higher rates of readmission (20.7% vs 11.5%, p = 0.006), blood transfusion (20.7% vs 10.5%, p = 0.006), and reoperation (8.6% vs 3.6%, p = 0.020). CONCLUSIONS: Of patients undergoing hernia repair concurrently with GI cancer resection, only 6.5% of patients underwent mVHR. mVHR was not associated with increased 30-day postoperative SSTIs vs pVHR but was associated with increased length of stay and other postoperative complications. Patient selection for concurrent mVHR must weigh the benefits of durable mesh-based repair with increased perioperative morbidity.
引用
- Farooq MS, Vargas GM, Shafique N, et al. Postoperative Outcomes of Concurrent Ventral Mesh Herniorrhaphy at the Time of Gastrointestinal Cancer Surgery. J Am Coll Surg. 2025. PMID: 41051076. doi:10.1097/XCS.0000000000001585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。